|
業務類別
|
Medical Devices |
|
業務概覽
|
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. |
| 公司地址
| One Glaukos Way, Aliso Viejo, CA, USA, 92656 |
| 電話號碼
| +1 949 367-9600 |
| 傳真號碼
| +1 949 367-9984 |
| 公司網頁
| https://www.glaukos.com |
| 員工數量
| 1094 |
| Mr. Thomas W. Burns |
Chairman of the Board and Chief Executive Officer |
美元 850.00K |
16/04/2026 |
| Mr. Joseph E. Gilliam |
President and Chief Operating Officer |
美元 584.85K |
16/04/2026 |
| Mr. Alex R. Thurman |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 486.20K |
16/04/2026 |
| Dr. Tomas Navratil |
Chief Development Officer |
美元 499.40K |
16/04/2026 |
|
|
| Ms. Aimee S. Weisner |
Independent Director |
16/04/2026 |
| Mr. David F. Hoffmeister |
Independent Director |
16/04/2026 |
| Dr. Gilbert H. Kliman, M.D. |
Independent Director |
16/04/2026 |
| Mr. Mark J. Foley |
Lead Independent Director |
16/04/2026 |
| Mr. Marc A. Stapley |
Independent Director |
16/04/2026 |
| Mr. Thomas W. Burns |
Chairman of the Board and Chief Executive Officer |
16/04/2026 |
| Ms. Denice M. Torres, J.D.,M.B.A. |
Independent Director |
16/04/2026 |
| Dr. Leana S. Wen, M. Sc.,M.D. |
Independent Director |
16/04/2026 |
|
|
|
|
